Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Bay Area's DNAnexus Scores $58M to Accelerate Expansion January 1, 2018 Ex-Genentechers' Denali Scores $1B+ Alzheimer's Deal With Takeda January 4, 2018 Genentech New Breast Cancer Cocktail Cuts Deaths in Phase III Study, Roche Stock Soars March 1, 2017